ES2556243T3 - Agentes terapéuticos que contienen bacteriófagos - Google Patents
Agentes terapéuticos que contienen bacteriófagos Download PDFInfo
- Publication number
- ES2556243T3 ES2556243T3 ES04743566.4T ES04743566T ES2556243T3 ES 2556243 T3 ES2556243 T3 ES 2556243T3 ES 04743566 T ES04743566 T ES 04743566T ES 2556243 T3 ES2556243 T3 ES 2556243T3
- Authority
- ES
- Spain
- Prior art keywords
- ncimb
- deposited
- aeruginosa
- panel
- therapeutic agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Panel de bacteriófagos adecuado para tratar una infección bacteriana que comprende o consiste en Pseudomonas aeruginosa, en el que cada miembro de dicho panel tiene una diferente especificidad de cepa para P. aeruginosa, y en el que el panel consiste en dos o más bacteriófagos seleccionados del grupo que consiste en: (i) las cepas de bacteriófagos depositadas NCIMB 41174, NCIMB 41175, NCIMB 41176, NCIMB 41177, NCIMB 41178, NCIMB 41179, NCIMB 41180 y NCIMB 41181 (depositadas en la National Collection of Industrial and Marine Bacteria, Aberdeen, Reino Unido); y (ii) mutantes de las cepas depositadas que conservan la capacidad de dirigirse a P. aeruginosa, en el que dicho mutante tiene una identidad en la secuencia de nucleótidos de al menos el 98% o al menos el 99% a lo largo de la totalidad de su genoma en comparación con el genoma de la pertinente cepa depositada.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0317240A GB0317240D0 (en) | 2003-07-23 | 2003-07-23 | Therapeutic agents |
GB0317240 | 2003-07-23 | ||
GB0410855A GB0410855D0 (en) | 2004-05-14 | 2004-05-14 | Therapeutic agents |
GB0410855 | 2004-05-14 | ||
PCT/GB2004/003237 WO2005009451A1 (en) | 2003-07-23 | 2004-07-23 | Bacteriophage-containing therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2556243T3 true ES2556243T3 (es) | 2016-01-14 |
Family
ID=34105984
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12195158.6T Active ES2527994T3 (es) | 2003-07-23 | 2004-07-23 | Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa |
ES04743566.4T Active ES2556243T3 (es) | 2003-07-23 | 2004-07-23 | Agentes terapéuticos que contienen bacteriófagos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12195158.6T Active ES2527994T3 (es) | 2003-07-23 | 2004-07-23 | Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa |
Country Status (7)
Country | Link |
---|---|
US (5) | US7807149B2 (es) |
EP (2) | EP2570130B1 (es) |
JP (2) | JP5731727B2 (es) |
AU (1) | AU2004258731B2 (es) |
CA (1) | CA2533352C (es) |
ES (2) | ES2527994T3 (es) |
WO (1) | WO2005009451A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527994T3 (es) * | 2003-07-23 | 2015-02-03 | Biocontrol Limited | Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa |
JP2008535480A (ja) * | 2005-03-04 | 2008-09-04 | ブレイズ ベンチャー テクノロジーズ リミテッド | 細菌の捕集方法及び捕集装置 |
CN100363489C (zh) * | 2005-06-16 | 2008-01-23 | 华中科技大学同济医学院附属同济医院 | 一株耐亚胺培南绿脓杆菌噬菌体及其用于治疗耐亚胺培南绿脓杆菌感染的用途 |
JP5127708B2 (ja) | 2005-07-12 | 2013-01-23 | マイクレオス べスローテン フェンノートシャップ | バクテリオファージ及びその使用 |
WO2007113657A1 (en) * | 2006-04-04 | 2007-10-11 | Centre National De La Recherche Scientifique - Cnrs | Process of production of bacteriophage compositions and methods in phage therapy field |
GB0704553D0 (en) * | 2007-03-09 | 2007-04-18 | Harper David R | Beneficial effects of bacteriophage treatments |
US9320795B2 (en) * | 2007-12-13 | 2016-04-26 | Zoctis Server LLC | Bacteriophage preparations and methods of use thereof |
US8956628B2 (en) * | 2007-12-13 | 2015-02-17 | Zoetis Products Llc | Bacteriophage preparations and method of use thereof |
KR20100093626A (ko) * | 2009-02-17 | 2010-08-26 | 서강대학교산학협력단 | 슈도모나스 애루지노사에 대한 파아지 치료 |
WO2010141135A2 (en) | 2009-03-05 | 2010-12-09 | Trustees Of Boston University | Bacteriophages expressing antimicrobial peptides and uses thereof |
TW201130980A (en) * | 2010-03-02 | 2011-09-16 | Univ Ishou | A new lytic phage specific to Klebsiella pneumoniae |
CA2837731C (en) | 2011-06-28 | 2018-05-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Controlled covalent attachment of bioactive bacteriophage for regulating biofilm development |
US8669226B2 (en) | 2011-10-07 | 2014-03-11 | Morehouse School Of Medicine | Antimicrobial compositions and methods of use thereof |
US10124027B2 (en) | 2012-05-04 | 2018-11-13 | Biocontrol Limited | Therapeutic bacteriophage compositions |
DE102013106455A1 (de) | 2013-06-20 | 2014-12-24 | Airbus Defence and Space GmbH | Verfahren zur Dekontamination von bakteriologischen Verunreinigungen |
PL405911A1 (pl) | 2013-11-04 | 2015-05-11 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Białko o aktywności hydrolitycznej wobec polisacharydowych otoczek bakteryjnych, polinukleotyd kodujący to białko, biologicznie czynny wektor, kompozycja zawierająca białko i jego zastosowanie |
US11058131B2 (en) | 2015-04-16 | 2021-07-13 | Kennesaw State University Research And Service Foundation, Inc. | Escherichia coli O157:H7 bacteriophage Φ241 |
US10517908B2 (en) | 2015-08-13 | 2019-12-31 | Armata Pharmaceuticals, Inc. | Therapeutic bacteriophage compositions |
US11732243B2 (en) * | 2016-04-08 | 2023-08-22 | Phico Therapeutics Ltd | Anti-bacterial compositions comparing lytic modified bacteriophage engineered to infect and kill different target bacteria |
US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
US20190142881A1 (en) * | 2016-04-25 | 2019-05-16 | Yale University | Bacteriophage compositions and uses thereof |
EP3579853A1 (en) | 2017-02-13 | 2019-12-18 | Biocontrol Limited | Therapeutic bacteriophage compositions |
CN109837251B (zh) * | 2017-11-27 | 2022-01-28 | 菲吉乐科(南京)生物科技有限公司 | 一种噬菌体保护剂及其制备方法和应用 |
US11654166B2 (en) | 2018-01-02 | 2023-05-23 | Armata Pharmaceuticals, Inc. | Therapeutic bacteriophage compositions for treating Staphylococcus infection |
WO2019136108A1 (en) | 2018-01-02 | 2019-07-11 | Ampliphi Biosciences Corporation | Bacteriophage compositions for treating pseudomonas infections |
CN108300723B (zh) * | 2018-01-17 | 2022-04-08 | 天津科技大学 | 应用于筛选生物被膜抑制剂的报告基因系统 |
CA3093658A1 (en) | 2018-02-07 | 2019-08-15 | Armata Pharmaceuticals, Inc. | Bacteriophage for treatment and prevention of bacteria-associated cancers |
CN112543595B (zh) | 2018-05-30 | 2022-11-01 | 莫尔豪斯医学院 | 抗微生物组合物,其制备方法和用途 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678750A (en) | 1984-10-18 | 1987-07-07 | Microlife Technics, Inc. | Method and compositions for use in the treatment of fireblight |
US4828999A (en) | 1986-07-21 | 1989-05-09 | Jackson Le Roy E | Bacteriophage prevention and control of harmful plant bacteria |
SU1472500A1 (ru) * | 1987-07-28 | 1989-04-15 | Тбилисский Научно-Исследовательский Институт Вакцин И Сывороток | Штамм бактериофага РSеUDомоNаS aeRUGINoSa, используемый дл идентификации и индикации микробов РSеUDомоNаS aeRUGINoSa |
US5032574A (en) | 1988-05-26 | 1991-07-16 | Invitron Corporation | Novel antimicrobial peptide |
US5242902A (en) | 1989-09-06 | 1993-09-07 | The Regents Of The University Of California | Defensin peptide compositions and methods for their use |
EP0650494A1 (en) | 1992-05-22 | 1995-05-03 | The Children's Hospital Of Philadelphia | Gastrointestinal defensins, cdna sequences and method for the production and use thereof |
DE69324918T2 (de) | 1993-02-24 | 1999-11-11 | Gunze Kk | Arznei gegen cystische fibrosen |
US5459235A (en) | 1993-03-19 | 1995-10-17 | The Regents Of The University Of California | Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils |
US5550109A (en) | 1994-05-24 | 1996-08-27 | Magainin Pharmaceuticals Inc. | Inducible defensin peptide from mammalian epithelia |
JP2000508322A (ja) | 1996-04-15 | 2000-07-04 | エヌワイエムオーエックス コーポレーション | バクテリオファージを含有する組成物および感染症を治療するためのバクテリオファージの使用方法 |
WO1998047521A1 (en) | 1997-04-24 | 1998-10-29 | Idaho Research Foundation, Inc. | Phages, methods for growing and detecting them and their use |
US20020037260A1 (en) | 1997-10-16 | 2002-03-28 | Budny John A. | Compositions for treating biofilm |
US6161036A (en) | 1997-12-25 | 2000-12-12 | Nihon Kohden Corporation | Biological signal transmission apparatus |
DE69931892T2 (de) | 1998-01-21 | 2006-12-21 | Defence Evaluation And Research Agency, Farnborough | Test auf Antibiotikumempfindlichkeit |
US20040208853A1 (en) * | 2000-01-11 | 2004-10-21 | Intralytix, Inc. | Method and device for sanitation using bacteriophages |
EP1250143A2 (en) * | 2000-01-11 | 2002-10-23 | Intralytix Inc. | Reduction in bacterial colonization by administering bacteriophage compositions |
US20020001590A1 (en) | 2000-04-20 | 2002-01-03 | Mount Sinai Hospital | Antibacterial therapy for multi-drug resistant bacteria |
US6485902B2 (en) | 2000-06-06 | 2002-11-26 | Thomas E. Waddell | Use of bacteriophages for control of escherichia coli O157 |
EP1305038B1 (en) | 2000-07-25 | 2005-10-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Bacteriophage having multiple host range |
US6461608B1 (en) | 2000-11-22 | 2002-10-08 | Nymox Pharmaceutical Corporation | Bacteriophage composition useful in treating food products to prevent bacterial contamination |
RU2186574C1 (ru) | 2001-01-24 | 2002-08-10 | Яфаев Рауэль Хасанянович | Препарат поливалентного бактериофага против синегнойной палочки, штаммы бактериофага bacteriophagum pseudomonas aeruginosa спбгма им. и.и. мечникова №05, №03, №06 и №07, используемые при приготовлении поливалентного препарата против синегнойной палочки |
DE60218473T2 (de) * | 2001-07-18 | 2007-11-08 | Instytut Immunologii I Terapii Doswiadczalnej - Pan | Verfahren zur herstellung polyvalenter bakteriophagenpräparationen zur behandlung bakterieller infektionen |
GB0300597D0 (en) * | 2003-01-10 | 2003-02-12 | Microbiological Res Authority | Phage biofilms |
US6804620B1 (en) | 2003-03-21 | 2004-10-12 | Advantest Corporation | Calibration method for system performance validation of automatic test equipment |
ES2527994T3 (es) * | 2003-07-23 | 2015-02-03 | Biocontrol Limited | Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa |
US20050051420A1 (en) | 2003-09-05 | 2005-03-10 | Sharper Image Corporation | Electro-kinetic air transporter and conditioner devices with insulated driver electrodes |
GB0704553D0 (en) | 2007-03-09 | 2007-04-18 | Harper David R | Beneficial effects of bacteriophage treatments |
-
2004
- 2004-07-23 ES ES12195158.6T patent/ES2527994T3/es active Active
- 2004-07-23 JP JP2006520908A patent/JP5731727B2/ja active Active
- 2004-07-23 US US10/565,347 patent/US7807149B2/en active Active
- 2004-07-23 EP EP12195158.6A patent/EP2570130B1/en active Active
- 2004-07-23 ES ES04743566.4T patent/ES2556243T3/es active Active
- 2004-07-23 WO PCT/GB2004/003237 patent/WO2005009451A1/en active Application Filing
- 2004-07-23 EP EP04743566.4A patent/EP1663265B1/en active Active
- 2004-07-23 CA CA2533352A patent/CA2533352C/en active Active
- 2004-07-23 AU AU2004258731A patent/AU2004258731B2/en active Active
-
2010
- 2010-10-04 US US12/897,741 patent/US8105579B2/en active Active
-
2011
- 2011-12-21 US US13/333,684 patent/US8388946B2/en active Active
-
2012
- 2012-11-02 JP JP2012242956A patent/JP5856556B2/ja active Active
-
2013
- 2013-02-01 US US13/757,655 patent/US9687514B2/en active Active
-
2017
- 2017-06-05 US US15/614,420 patent/US20180055895A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005009451A9 (en) | 2006-05-18 |
US20110020290A1 (en) | 2011-01-27 |
JP2013049700A (ja) | 2013-03-14 |
US8105579B2 (en) | 2012-01-31 |
CA2533352A1 (en) | 2005-02-03 |
US20070190033A1 (en) | 2007-08-16 |
JP2006528166A (ja) | 2006-12-14 |
US20130209408A1 (en) | 2013-08-15 |
EP1663265A1 (en) | 2006-06-07 |
EP2570130A1 (en) | 2013-03-20 |
CA2533352C (en) | 2016-01-19 |
US7807149B2 (en) | 2010-10-05 |
US20180055895A1 (en) | 2018-03-01 |
US20120114611A1 (en) | 2012-05-10 |
EP2570130B1 (en) | 2014-11-26 |
ES2527994T3 (es) | 2015-02-03 |
WO2005009451A1 (en) | 2005-02-03 |
JP5856556B2 (ja) | 2016-02-10 |
US8388946B2 (en) | 2013-03-05 |
AU2004258731A1 (en) | 2005-02-03 |
JP5731727B2 (ja) | 2015-06-10 |
AU2004258731B2 (en) | 2010-02-25 |
US9687514B2 (en) | 2017-06-27 |
EP1663265B1 (en) | 2015-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2556243T3 (es) | Agentes terapéuticos que contienen bacteriófagos | |
Henriksen et al. | P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage–ciprofloxacin combination: —monitoring the phage–P. aeruginosa biofilms interactions | |
Al-Anany et al. | Temperate phage-antibiotic synergy eradicates bacteria through depletion of lysogens | |
Weitere et al. | Grazing resistance of Pseudomonas aeruginosa biofilms depends on type of protective mechanism, developmental stage and protozoan feeding mode | |
Fu et al. | Inhibition of Pseudomonas aeruginosa biofilm formation by traditional Chinese medicinal herb Herba patriniae | |
Jamal et al. | Isolation and characterization of a bacteriophage and its utilization against multi-drug resistant Pseudomonas aeruginosa-2995 | |
Moulton‐Brown et al. | Rapid evolution of generalized resistance mechanisms can constrain the efficacy of phage–antibiotic treatments | |
CY1118006T1 (el) | Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων | |
BR9913935A (pt) | Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo | |
JP2006528166A5 (es) | ||
BR0014663A (pt) | Moléculas de ácido nucléico para a detecção de bactérias e unidades filogenéticas de bactérias | |
Hajialilo et al. | Molecular characterization of bacterial, viral and fungal endosymbionts of Acanthamoeba isolates in keratitis patients of Iran | |
DE69835536D1 (de) | Zusammensetzungen zur behandlung von staphylococcus aureus infektionen | |
Nowicki et al. | Phenethyl isothiocyanate inhibits shiga toxin production in enterohemorrhagic Escherichia coli by stringent response induction | |
Das et al. | Genome plasticity as a paradigm of antibiotic resistance spread in ESKAPE pathogens | |
Kock et al. | Orientia tsutsugamushi is highly susceptible to the RNA polymerase switch region inhibitor Corallopyronin A in vitro and in vivo | |
Mauro et al. | The microcosm mediates the persistence of shiga toxin-producing Escherichia coli in freshwater ecosystems | |
Rahmat Ullah et al. | Effectiveness of a lytic phage SRG1 against vancomycin‐resistant Enterococcus faecalis in compost and soil | |
WO2005046454A3 (en) | Methods of using gelsolin to treat or prevent bacterial sepsis | |
Grami et al. | Siphoviridae bacteriophage treatment to reduce abundance and antibiotic resistance of Pseudomonas aeruginosa in wastewater | |
US8440446B2 (en) | Bacteriophage strains for the treatment of bacterial infections, especially drug resistant strains of the genus Enterococcus | |
Sharma et al. | Incidence of multi-drug resistance in Escherichia coli strains isolated from three lakes of tourist attraction (Mirik lake, Jorepokhari lake and Nakhapani lake) of Darjeeling hills, India | |
AU2002354900A1 (en) | Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections | |
EA200100700A1 (ru) | Гены и белки и их применение | |
Puiu et al. | Bacteriophage gene products as potential antimicrobials against tuberculosis |